Navigation Links
Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Date:6/8/2009

y combination of these agents were eligible for enrollment and immediately switched to a starting dose of 6.0 grams per day of Zerenex (ferric citrate). Patients were treated with Zerenex (ferric citrate) for four weeks and were titrated weekly to achieve and maintain normal serum phosphorus levels, between 3.5 to 5.5 mg/dL, the therapeutic goal.

Although designed primarily as a safety study, key efficacy parameters were evaluated, with results as follows:

At baseline:

  • Baseline mean + standard deviation (SD) serum phosphorus was approximately 5.9 + 1.5 mg/dL immediately prior to the switch to Zerenex (ferric citrate);
  • The average daily dose of PhosLo(R) (calcium acetate) was 6.9 grams per day and for Renagel(R) (sevelamer hydrochloride) was 9.9 grams per day, for patients not on combination therapy prior to the switch to Zerenex (ferric citrate).

Following the treatment period (four weeks on Zerenex):

  • At the end of the treatment period (after four weeks on Zerenex) the mean + SD serum phosphorus was approximately 5.4 + 1.3 mg/dL;
  • The average daily dose of Zerenex (ferric citrate) at the end of four weeks of treatment was 6.8 grams per day.

In the subset of patients who had a serum phosphorus above the normal range (> 5.5 mg/dL) immediately prior to the switch to Zerenex (n = 29), the mean (SD) baseline serum phosphorus was 7.0 (1.1) mg/dL, and at the end of treatment with Zerenex the mean (SD) serum phosphorus was 5.6 (1.6) mg/dL.

In the Phase 2 study, there were four serious adverse events which were deemed unrelated to Zerenex. Darkened stool was reported in the study and was associated with the presence of iron in the gastrointestinal tract. With the exception of the reporting of darkened stool
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
2. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
3. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
4. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2007 Financial Results on Thursday, October 25, at 8:30 A.M. EDT
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2007 Financial Results
7. Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations
8. Keryx Biopharmaceuticals Announces Additions to Management Team
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST
10. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2007 Financial Results
11. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/27/2014)... The report “Smart Highway Market by ... Monitoring), and by Display (Variable Message Signs, Digital ... global market into various sub-segments with in-depth analysis ... drivers and restraints for this market with insights ... market tables and 37 figures spread through 141 ...
(Date:10/27/2014)... -- Investor-Edge has initiated coverage on the ... ), Insmed Inc. (NASDAQ: INSM ), BioCryst ... (NASDAQ: DYAX ), and Oncothyreon Inc. (NASDAQ: ... accessed at: http://investor-edge.com/register . On Friday, ... up 0.69%, the Dow Jones Industrial Average advanced 0.76%, ...
(Date:10/25/2014)... The report “Adipic Acid Market by ... Global Trends & Forecast to 2019” report analyzes ... drivers, opportunities, and trends in different regions. , ... spread through 217 slides and in-depth TOC on ... to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , Early buyers will ...
(Date:10/25/2014)... According to new market research report "Data Center ... Telecom), by Design Types (Electrical, Mechanical), and by ... Tier 4) - Global Forecast to 2019", published ... Construction Market into various segments with an in-depth ... also identifies the factors driving this market, various ...
Breaking Biology Technology:Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 2Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 3Smart Highway Market by Technology, and Display Expected to Reach $27.992.0 Million by 2019- New Report by MarketsandMarkets 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 2Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 3Data Center Construction Market Worth $22.73 Billion by 2019 - New Report by MarketsandMarkets 4
... NEW YORK, March 9, 2011 Reportlinker.com announces ... in its catalogue: World Market ... and What,s Not, The ... predictions made about the molecular diagnostics but to ...
... 2011 SPX Corporation (NYSE: SPW ) ... B.W. Murdoch Ltd, a leading engineering company supplying processing ... is based in Auckland, New Zealand. Terms of the ... has decades of experience in the New Zealand dairy, ...
... 2011 AccessClosure, Inc., the U.S. market segment ... from the first published study* (Journal of NeuroInterventional ... different vascular closure devices (VCD) as the primary ... the discomfort associated with the Mynx 5F Vascular ...
Cached Biology Technology:Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 2Reportlinker Adds World Market for Molecular Diagnostics: Potential and Reality, What's Hot and What's Not , The 3SPX Announces Acquisition of B.W. Murdoch Ltd, Broadening Process Engineering and Project Management Capabilities in New Zealand and the Asia Pacific Region 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 2Significant Reduction in Pain With the Mynx Vascular Closure Device Versus Angio-Seal Device 3
(Date:10/28/2014)... of the tragic realities of cancer is that ... toxic and their effectiveness varies unpredictably from patient ... poised to change this reality by rapidly assessing ... an individual,s cancer before chemotherapy begins. , A ... by Assistant Professor Melissa Skala has developed the ...
(Date:10/28/2014)... announced awards to expand the Office of Rare ... Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases Clinical ... scientists at 22 consortia will work with 98 ... investigate new treatments for patients with rare diseases. ... in fiscal 2014 funding from NIH. , Rett ...
(Date:10/28/2014)... be building a hybrid micro-grid which will integrate ... in the region, the hybrid micro-grid will test ... diesel, storage and power-to-gas technologies, and ensure these ... built under the new Renewable Energy Integration Demonstrator- ... located offshore at Semakau Landfill and is expected ...
Breaking Biology News(10 mins):Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3NTU to build region's first renewable energy integration demonstration micro-grid 2NTU to build region's first renewable energy integration demonstration micro-grid 3
... all the genetic sequences in living organisms, has leaned ... the blueprint, unfortunately, has been unintelligible, with no good ... link genomic features to cell function. , A national ... non-profit research center, and Pacific Northwest National Laboratory (PNNL), ...
... Medicine have identified a link between a critical cancer ... be expressed in a number of EBV-associated cancers. Their ... human B cells from the immune system into cancerous ... , Erle S. Robertson, PhD, Associate Professor of Microbiology ...
... target in their fight against a dangerous bacterium that ... implants such as catheters, artificial joints and heart valves. ... epidermidis has, for the first time, been shown to ... that would otherwise kill the bacteria, according to scientists ...
Cached Biology News:Fleshing out the genome 2Defensins neutralize anthrax toxin 2Substance protects resilient staph bacteria 2
...
... as an internal standard for the quantification ... spectrometry. 5-OxoETE is a polyunsaturated keto acid ... human neutrophils. It stimulates cytosolic calcium levels ... nM. 5-OxoETE selectively stimulates the migration and ...
Mouse monoclonal antibody raised against a full length recombinant ATF3. NCBI Entrez Gene ID = ATF3...
... pAcAB4 vector is a 10.0 kb Autographa ... two,copies of the AcNPV polyhedrin promoter and ... first p10,promoter is a Sma I cloning ... Upstream of this,an inverted polyhedrin promoter has ...
Biology Products: